Dihydroartemisinin

Synonyms: 双氢青蒿素; Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol
Dihydroartemisinin 是一种具有口服活性的 Artemisinin (MS-M42990) 代谢物和抗疟剂,可通过抑制 NF-κB 活化来诱导自噬 (Autophagy)、促进 ROS 蓄积,在食管癌细胞中展现出抗癌活性,并对日本血吸虫 (Schistosoma japonicum) 的童虫和成虫具有杀血吸虫活性,可降低虫荷,表现出抗寄生虫 (Antiparasitic) 活性,可用于多发性骨髓瘤、早幼粒细胞白血病、食管癌以及日本血吸虫感染的相关研究。
产品编号: MS-G27879 纯度: 98.0% CAS No.: 71939-50-9 分子式: C15H24O5 分子量: 284.35
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Dihydroartemisinin 是一种具有口服活性的 Artemisinin (MS-M42990) 代谢物和抗疟剂,可通过抑制 NF-κB 活化来诱导自噬 (Autophagy)、促进 ROS 蓄积,在食管癌细胞中展现出抗癌活性,并对日本血吸虫 (Schistosoma japonicum) 的童虫和成虫具有杀血吸虫活性,可降低虫荷,表现出抗寄生虫 (Antiparasitic) 活性,可用于多发性骨髓瘤、早幼粒细胞白血病、食管癌以及日本血吸虫感染的相关研究。

生物实验数据

生物活性 Dihydroartemisinin is an orally active metabolite of Artemisinin (MS-M42990) and an antimalarial agent that induces autophagy by inhibiting NF-κB activation, promotes ROS accumulation, exhibits anticancer activity in esophageal cancer cells, and displays schistosomicidal activity against schistosomula and adult worms of Schistosoma japonicum by reducing worm burden, thereby demonstrating antiparasitic activity, and it can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection.
IC50 & Target HeLa cells proliferation:24.74 ± 0.38 μM, SGC-7901 cells viability:5.191 μM (48h), HGC-27 cells viability:5.608 μM (48h)
体外研究
(In Vitro)

Dihydroartemisinin (10-40 μM; 24 h) 可在体外以剂量依赖的方式诱导多发性骨髓瘤 RPMI 8226 细胞发生包括线粒体自噬在内的功能性自噬。
Dihydroartemisinin (10-40 μM; 12 h) 可通过抑制 IκBα 磷酸化、阻止 RelA/p65 核转位并降低 DNA 结合活性,抑制多发性骨髓瘤 RPMI 8226 细胞中的 NF-κB 活性。
Dihydroartemisinin (10-40 μM; 15-24 h) 可诱导多发性骨髓瘤 RPMI 8226 细胞和早幼粒细胞白血病 NB4 细胞发生自噬,该过程依赖于 NF-κB 抑制介导的 FHC 和 MnSOD 表达下调,进而导致 ROS 积累并驱动自噬激活。
Dihydroartemisinin (2.5-120 μmol/L; 24 h) 可在体外以剂量依赖方式降低食管癌 Eca109 和 Ec9706 细胞的存活率。
Dihydroartemisinin (80 μmol/L; 24 h) 可增强食管癌 Eca109 和 Ec9706 细胞对光动力方法诱导凋亡的敏感性,将 Eca109 细胞的凋亡率提升至 20.9%,Ec9706 细胞的凋亡率提升至 21.8%。

Cell Autophagy Assay

Cell Line: human multiple myeloma RPMI 8226 cells
Concentration: 10 μM, 20 μM, 40 μM
Incubation Time: 24 h
Result: Induced dose-dependent accumulation of AVOs (12.5% AVO-positive cells at 20 μM, 17% at 40 μM).
Increased LC3-II protein levels in a dose-dependent manner.
Decreased p62 protein levels in a dose-dependent manner.
Further increased LC3-II levels when cotreated with CQ compared to DHA alone.
Increased autophagic vacuoles and autophagosomes containing damaged mitochondria via transmission electron microscopy.
Increased colocalization of LC3 puncta with mitochondria via immunofluorescence.

Cell Viability Assay

Cell Line: human esophageal cancer Eca109 and Ec9706 cells
Concentration: 2.5-120 μmol/L
Incubation Time: 24 h
Result: Reduced the viability of Eca109 and Ec9706 cells in a dose-dependent manner relative to untreated cells.

Apoptosis Analysis

Cell Line: human esophageal cancer Eca109 and Ec9706 cells (combined with photodynamic therapy)
Concentration: 80 μmol/L
Incubation Time: 24 h
Result: Increased the apoptosis rate from 7.7% to 12.1% in Eca109 cells and from 5.5% to 12.7% in Ec9706 cells when used as single treatment.
Increased the apoptosis rate to 20.9% in Eca109 cells and 21.8% in Ec9706 cells when combined with PDT, a significantly greater increase than either single treatment (p<0.05).
体内研究
(In Vivo)

Dihydroartemisinin (200-600 mg/kg;口服;每日一次;连续 3 天) 可使感染日本血吸虫 S. japonicum 的昆明小鼠体内血吸虫童虫的总虫荷减少 69.2%-90.6%。

Animal Model: Kunming strain (20-24 g, percutaneously infected with 39-41 Schistosoma japonicum cercariae)
Dosage: 200 mg/kg; 300 mg/kg; 400 mg/kg; 600 mg/kg
Administration: p.o.; daily; 3 days
Result: Reduced total-worm burden by 69.2% and female-worm burden by 62.2% when administered on days 6-8 post-infection at 200 mg/kg.
Reduced total-worm burden by 80.7% and female-worm burden by 75.6% when administered on days 6-8 post-infection at 300 mg/kg.
Reduced total-worm burden by 87.1% (statistically greater than 200 mg/kg) and female-worm burden by 87.1% when administered on days 6-8 post-infection at 400 mg/kg.
Reduced total-worm burden by 90.6% (statistically greater than 200 mg/kg) and female-worm burden by 90.2% when administered on days 6-8 post-infection at 600 mg/kg.
Reduced total-worm burden by 73.9% and female-worm burden by 83.8% when administered on days 34-36 post-infection at 200 mg/kg.
Reduced total-worm burden by 75.0% and female-worm burden by 92.9% when administered on days 34-36 post-infection at 300 mg/kg.
Reduced total-worm burden by 84.2% and female-worm burden by 94.1% (statistically greater than 200 mg/kg) when administered on days 34-36 post-infection at 400 mg/kg.
Reduced total-worm burden by 85.5% and female-worm burden by 95.3% (statistically greater than 200 mg/kg) when administered on days 34-36 post-infection at 600 mg/kg.
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT01075945University of Khartoum|Southeast University, China
Malaria
2010-02PHASE4
NCT01899820Sabah Ahmed Omar|World Bank|Kenya Medical Research Institute
Malaria
2013-04PHASE3
NCT07082205Liverpool School of Tropical Medicine|National Institute of Allergy and Infectious Diseases (NIAID)|Centers for Disease Control and Prevention
Malaria|Severe Malaria|Severe Anaemia|Post Discharge
2025-05-02PHASE3
性状 固体
颜色 White to off-white

化学信息

分子量 284.35
分子式 C15H24O5
CAS No. 71939-50-9
别名 双氢青蒿素; Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 5.25 mg/mL (18.46 mM), Suspension.
10% DMSO+90% Saline: < 5.25 mg/mL (18.46 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.2 mg/mL (18.29 mM), Suspension.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 25 mg/mL (87.92 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 10 mg/mL (35.17 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol / DMSO1 mM3.5168 mL17.5840 mL35.1679 mL87.9198 mL
5 mM0.7034 mL3.5168 mL7.0336 mL17.5840 mL
10 mM0.3517 mL1.7584 mL3.5168 mL8.7920 mL
15 mM0.2345 mL1.1723 mL2.3445 mL5.8613 mL
20 mM0.1758 mL0.8792 mL1.7584 mL4.3960 mL
25 mM0.1407 mL0.7034 mL1.4067 mL3.5168 mL
30 mM0.1172 mL0.5861 mL1.1723 mL2.9307 mL
DMSO40 mM0.0879 mL0.4396 mL0.8792 mL2.1980 mL
50 mM0.0703 mL0.3517 mL0.7034 mL1.7584 mL
60 mM0.0586 mL0.2931 mL0.5861 mL1.4653 mL
80 mM0.0440 mL0.2198 mL0.4396 mL1.0990 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础